Sutro Biopharma
STRO
130 hedge funds and large institutions have $216M invested in Sutro Biopharma in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 31 reducing their positions, and 11 closing their positions.
121% more call options, than puts
Call options by funds: $268K | Put options by funds: $121K
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
65% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 31
17% more capital invested
Capital invested by funds: $185M → $216M (+$31.3M)
9% more funds holding
Funds holding: 119 → 130 (+11)
0.1% less ownership
Funds ownership: 7.72% → 7.63% (-0.1%)
Top Buyers
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$3.19M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.84M |
| 3 |
Goldman Sachs
New York
|
+$2.73M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.51M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.99M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$9.13M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.68M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.6M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$2.04M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.37M |
STRO Hedge Fund Activity: Q3 2024 in Review
130 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2024, worth a combined $216M — up 17% from $185M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new STRO positions and 11 closed out — a net gain of 12 holders — while 51 added to existing stakes and 31 trimmed.
The largest buyer was Bank of Montreal, opening a new position worth an estimated $3.19M. The largest seller was Millennium Management, cutting an estimated $9.13M.
- 130 institutional investors held Sutro Biopharma (STRO) as of Q3 2024, up from 119 in Q2 2024.
- Funds reported $216M of Sutro Biopharma stock for Q3 2024, up 17% quarter-over-quarter.
- 23 funds opened new Sutro Biopharma positions in Q3 2024 and 11 closed out, a net change of +12 holders.
- The largest Sutro Biopharma buyer in Q3 2024 was Bank of Montreal, an estimated $3.19M added.
- The largest Sutro Biopharma seller in Q3 2024 was Millennium Management, an estimated $9.13M sold.
Based on aggregated 13F filings for Q3 2024.